SG11202109892UA - Therapeutic uses of dulaglutide - Google Patents
Therapeutic uses of dulaglutideInfo
- Publication number
- SG11202109892UA SG11202109892UA SG11202109892UA SG11202109892UA SG 11202109892U A SG11202109892U A SG 11202109892UA SG 11202109892U A SG11202109892U A SG 11202109892UA SG 11202109892U A SG11202109892U A SG 11202109892UA
- Authority
- SG
- Singapore
- Prior art keywords
- dulaglutide
- therapeutic uses
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829717P | 2019-04-05 | 2019-04-05 | |
| PCT/US2019/059631 WO2020204998A1 (en) | 2019-04-05 | 2019-11-04 | Therapeutic uses of dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109892UA true SG11202109892UA (en) | 2021-10-28 |
Family
ID=68732046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109892U SG11202109892UA (en) | 2019-04-05 | 2019-11-04 | Therapeutic uses of dulaglutide |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11890325B2 (en) |
| EP (1) | EP3946428A1 (en) |
| KR (2) | KR20230132627A (en) |
| CN (2) | CN114732897A (en) |
| AU (2) | AU2019439626B2 (en) |
| BR (1) | BR112021017315A2 (en) |
| CA (2) | CA3177693A1 (en) |
| EA (1) | EA202192296A1 (en) |
| IL (1) | IL285765A (en) |
| MA (1) | MA55467A (en) |
| MX (1) | MX2021012177A (en) |
| SG (1) | SG11202109892UA (en) |
| TW (2) | TW202400213A (en) |
| WO (1) | WO2020204998A1 (en) |
| ZA (1) | ZA202106250B (en) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503963A (en) | 1996-02-06 | 2001-03-27 | イーライ・リリー・アンド・カンパニー | Diabetes treatment |
| ATE346093T1 (en) | 2000-06-16 | 2006-12-15 | Lilly Co Eli | ANALOGUE OF GLUCAGON-LIKE PEPTIDE-1 |
| EA005584B1 (en) | 2000-12-07 | 2005-04-28 | Эли Лилли Энд Компани | Glp-1 fusion proteins |
| US20040209803A1 (en) | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
| SI1641823T1 (en) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Glp-1 analog fusion proteins |
| EP2168982A1 (en) | 2004-12-22 | 2010-03-31 | Eli Lilly & Company | GLP-1 analog fusion protein formulations |
| WO2009009562A2 (en) | 2007-07-10 | 2009-01-15 | Eli Lilly And Company | Glp-1-fc fusion protein formulation |
| KR101927068B1 (en) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR102578135B1 (en) | 2013-05-22 | 2023-09-13 | 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 | Extended release of neuregulin for treating heart failure |
| WO2015013762A1 (en) | 2013-07-29 | 2015-02-05 | Sg Ventures Pty Limited | Metallic pigments and method of coating a metallic substrate |
| US20190091295A1 (en) | 2016-03-04 | 2019-03-28 | Novo Nordisk A/S | Liraglutide in Renal Conditions |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| EP3275438B2 (en) * | 2016-07-29 | 2023-09-13 | Kowa Company, Ltd. | Methods of preventing cardiovascular events in residual risk dyslipidemic populations |
| DK3630164T3 (en) | 2017-06-01 | 2023-10-02 | Lilly Co Eli | Dulaglutide for the treatment of chronic kidney disease |
-
2019
- 2019-09-25 CA CA3177693A patent/CA3177693A1/en active Pending
- 2019-09-25 CA CA3056663A patent/CA3056663C/en active Active
- 2019-10-31 TW TW112117900A patent/TW202400213A/en unknown
- 2019-10-31 TW TW108139459A patent/TWI804692B/en active
- 2019-11-04 BR BR112021017315A patent/BR112021017315A2/en unknown
- 2019-11-04 CN CN202210427909.XA patent/CN114732897A/en active Pending
- 2019-11-04 KR KR1020237030298A patent/KR20230132627A/en not_active Application Discontinuation
- 2019-11-04 MA MA055467A patent/MA55467A/en unknown
- 2019-11-04 CN CN201980095007.7A patent/CN113631181A/en active Pending
- 2019-11-04 AU AU2019439626A patent/AU2019439626B2/en active Active
- 2019-11-04 US US17/599,621 patent/US11890325B2/en active Active
- 2019-11-04 EA EA202192296A patent/EA202192296A1/en unknown
- 2019-11-04 EP EP19812886.0A patent/EP3946428A1/en active Pending
- 2019-11-04 SG SG11202109892U patent/SG11202109892UA/en unknown
- 2019-11-04 MX MX2021012177A patent/MX2021012177A/en unknown
- 2019-11-04 KR KR1020217031248A patent/KR20210134713A/en active Application Filing
- 2019-11-04 WO PCT/US2019/059631 patent/WO2020204998A1/en unknown
-
2021
- 2021-08-22 IL IL285765A patent/IL285765A/en unknown
- 2021-08-27 ZA ZA2021/06250A patent/ZA202106250B/en unknown
-
2022
- 2022-12-30 AU AU2022291679A patent/AU2022291679A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3056663A1 (en) | 2020-10-05 |
| WO2020204998A1 (en) | 2020-10-08 |
| EA202192296A1 (en) | 2022-01-21 |
| KR20230132627A (en) | 2023-09-15 |
| AU2019439626A1 (en) | 2021-09-16 |
| TWI804692B (en) | 2023-06-11 |
| TW202103729A (en) | 2021-02-01 |
| MA55467A (en) | 2022-02-09 |
| MX2021012177A (en) | 2021-11-04 |
| EP3946428A1 (en) | 2022-02-09 |
| US11890325B2 (en) | 2024-02-06 |
| CA3056663C (en) | 2022-10-18 |
| CA3177693A1 (en) | 2020-10-05 |
| KR20210134713A (en) | 2021-11-10 |
| CN114732897A (en) | 2022-07-12 |
| IL285765A (en) | 2021-10-31 |
| AU2019439626B2 (en) | 2022-10-13 |
| BR112021017315A2 (en) | 2021-11-16 |
| TW202400213A (en) | 2024-01-01 |
| CN113631181A (en) | 2021-11-09 |
| ZA202106250B (en) | 2023-04-26 |
| AU2022291679A1 (en) | 2023-02-02 |
| US20220202908A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272410A (en) | Cytokine conjugates for the treatment of autoimmune diseases | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL282007A (en) | Medicament for the treatment of chronic cough | |
| GB201900702D0 (en) | Therapy | |
| IL286079A (en) | Imidazolonylquinoline compounds and therapeutic uses thereof | |
| IL292657A (en) | Therapeutic derivatives of interleukin-22 | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| IL286000A (en) | Esketamine for the treatment of depression | |
| ZA202105399B (en) | Use of spiropidion | |
| EP4041267A4 (en) | Yeast for the treatment of allergy | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| GB201907305D0 (en) | Treatment of conditions | |
| EP4096704A4 (en) | Therapeutic uses of dulaglutide | |
| GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
| IL289338A (en) | Therapeutic interactions of leucomethylthioninium | |
| GB201909438D0 (en) | Treatment of diseases | |
| GB201812861D0 (en) | Methods of administering therapy | |
| GB201917253D0 (en) | Treatment of conditions | |
| GB201904282D0 (en) | Treatment of osteoporotic diseases | |
| IL290983A (en) | Methods of treatment | |
| GB201909732D0 (en) | Cardiac therapeutic | |
| GB201918853D0 (en) | Methods of treatment | |
| GB201919036D0 (en) | Therapy | |
| GB201904764D0 (en) | Treatment of ophthalmological conditions |